dcsimg Aranesp® (darbepoetin alfa) – Dosing Options
› Email› Print

Aranesp® offers multiple dosing and administration options

Once weekly. Once every 2 weeks. Once every 4 weeks.

Aranesp® provides a longer duration of action*

Once weekly. Once every 2 weeks. Once every 4 weeks.

Aranesp® QW and Q2W dosing provides 66% to 83% fewer injections compared to TIW dosing1

Once weekly. Once every 2 weeks. Once every 4 weeks. Once weekly. Once every 2 weeks. Once every 4 weeks.

Important Safety Information

  • Control hypertension prior to initiating and during treatment with Aranesp®.
  • Aranesp® increases the risk of seizures in patients with CKD. Monitor patients closely for new-onset seizures, premonitory symptoms, or change in seizure frequency.

Scroll down for additional Important Safety Information

Abbreviations and References:
CKD = chronic kidney disease; HD = hemodialysis; PD = peritoneal dialysis; QW = once weekly; Q2W = once every 2 weeks; Q4W = once every 4 weeks; TIW = three times a week.
UltraSafe® is a registered trademark of Safety Syringes, Inc.
Reference: 1. Aranesp® (darbepoetin alfa) prescribing information, Amgen. 2. Detournay B, Aden G, Fabregas X, Lattarulo M, Lebouvier G. Prefilled disposable syringes vs conventional injection systems: European medicoeconomic analysis. EHP. 1998;4(4):109-113. 3. UltraSafe® Needle Guards [brochure]. Carlsbad, CA: Safety Syringes, Inc.; 2007. http://www.safetysyringes.com/pdf/25-NG_English2007cfo.pdf. Accessed December 4, 2014.

Biotechnology by Amgen®